Investing.com - Hims & Hers Health (NYSE:HIMS) 株は木曜日の時間外取引で4.1%下落した。これはブルームバーグの報道を受けたもので、連邦取引委員会（FTC）が1年以上にわたりこの遠隔医療会社の事業慣行を調査していることが明らかになった。

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company’s business practices for ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

The U.S. Federal Trade Commission is probing complaints about Telehealth platform Hims & Hers regarding its advertising and ...

Shares of Hims & Hers (HIMS) are down 92c, or 2%, to $45.09 in pre-market trading after GoodRx (GDRX) announced that all strengths of Ozempic and Wegovy pens are available to eligible self-paying ...

コンプレックス系の医薬品などをオンラインで販売するHims & Hers Health (以下、Hims) が発表した 2025年1〜3月期（Q1）決算は、売上高が前年同期比111 ...